Despite extensive research, the median survival remains dismal at 12–15 months.1 The latest classification of central nervous system (CNS) tumors categorizes gliomas into a diverse group of glial-derived brain tumors, with GBM being the most aggressive grade IV subtype, characterized by an isocitrate dehydrogenase (IDH) wild-type status. This evidence concerns the gene IDH1 and glioma.